Xontogeny, LLC - Aug 27, 2021 Form 4 Insider Report for Landos Biopharma, Inc. (LABP)

Role: Director
Signature: /s/ Christopher Garabedian for Xontogeny, LLC, By: Christoph Garabedian, its Chief Executive Officer
Stock symbol: LABP
Transactions as of: Aug 27, 2021
Transactions value $: $0
Form type: 4
Date filed: 8/31/2021, 09:35 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LABP	Stock Option (Right to Buy)	Award	$0	+10.7K		$0.00	10.7K	Aug 27, 2021	Common stock	10.7K	$14.18	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on August 27, 2021, subject to the Fred Callori's continuous service with the Issuer on each such date.
F2	Consists of a proportionate interest in stock options awarded to Mr. Callori in connection with his role as a member of the Issuer's Board of Directors. Mr. Callori serves as an officer of Xontogeny, LLC. Xontogeny may be deemed to have an indirect pecuniary interest in the securities reported herein because Xontogeny has the right to receive the director compensation provided in respect of Mr. Callori's board service through a partial management fee offset. Christoph Garabedian is the Chief Executive Officer of Xontogeny.
F3	Each of the Reporting Persons disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.